Vir Biotechnology Inc reports results for the quarter ended in September - Earnings Summary

Vir Biotechnology

02/11/2023 21:44

* Vir Biotechnology Inc  VIR.OQ  reported a quarterly
adjusted
loss of $1.22​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of $1.30.  The mean expectation of nine analysts for the
quarter was for a loss of $1.21 per share. Wall Street expected
results to range from $-1.49 to -88 cents per share.
    * Revenue fell 99.3% to $2.64 million from a year ago;
analysts
expected $10.24 million. 
    * Vir Biotechnology Inc's reported EPS for the quarter was a
loss
of $1.22​.
    * The company reported a quarterly loss of $163.41 million.
    * Vir Biotechnology Inc shares had fallen by 16.9% this
quarter and lost 69.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.4%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Vir
Biotechnology
Inc is $23.50 

This summary was machine generated from LSEG data November 2 at
09:43 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -1.21          -1.22          Missed
 Jun. 30 2023      -1.20          -1.45          Missed
 Mar. 31 2023      -0.87          -1.06          Missed
 Dec. 31 2022      -0.39          -0.76          Missed